

Multiple Myeloma (Kahler Disease) (Oncology) - Drugs in Development, 2021

<https://marketpublishers.com/r/M2F1D6CB192AEN.html>

Date: December 2021

Pages: 2980

Price: US\$ 2,500.00 (Single User License)

ID: M2F1D6CB192AEN

Abstracts

Multiple Myeloma (Kahler Disease) (Oncology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) – Drugs In Development, 2021, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key

players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 15, 128, 143, 11, 15, 218, 54 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 20, 23, 9, 41 and 10 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).

The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler

Disease) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Multiple Myeloma (Kahler Disease) - Overview
- Multiple Myeloma (Kahler Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
- Multiple Myeloma (Kahler Disease) - Drug Profiles
- Multiple Myeloma (Kahler Disease) - Dormant Projects
- Multiple Myeloma (Kahler Disease) - Discontinued Products
- Multiple Myeloma (Kahler Disease) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

- Number of Products under Development for Multiple Myeloma (Kahler Disease), 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Products under Development by Companies, 2021
- Products under Development by Universities/Institutes, 2021
- Number of Products by Stage and Target, 2021
- Number of Products by Stage and Mechanism of Action, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
- Multiple Myeloma (Kahler Disease) - Dormant Projects, 2021
- Multiple Myeloma (Kahler Disease) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Multiple Myeloma (Kahler Disease) (Oncology) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/M2F1D6CB192AEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M2F1D6CB192AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970